Independent cancer research: Aiom calls for more public funding
At the Rome congress, Aiom calls for more public resources for independent oncology research and explains how it differs from industry-funded research.

The Italian Association of Medical Oncology (Aiom) is calling for more public resources for independent oncology research, that is, research conducted by universities and clinical groups without funding from a pharmaceutical company.12 This was said by president Massimo Di Maio at the association’s XXVIII national congress, held in Rome from 13 to 15 November, which brings together about 3,000 specialists.12
What is the difference between independent research and industry research?
According to Di Maio, independent academic research can answer very useful questions for improving clinical practice, particularly those concerning the optimisation of how therapies are used.12 He notes that these questions are often not addressed by industry-sponsored research, whose fundamental goal is to bring drugs to registration.12 Di Maio recalls that Italy has a great tradition in this field: cooperative groups have produced studies capable of changing clinical guidelines.12
Why is the sector struggling today?
Di Maio attributes the recent difficulties to two factors: more complex procedures and the cost of treatments, which in studies must be used outside the coverage of the National Health Service (Ssn). For this reason, he says, studies often become unfeasible.12 Francesco Perrone, president of the Aiom Foundation, speaks of independent clinical research being “in crisis” in Italy and of a sector that needs concrete action to become fully competitive again.34
What Aiom asks of institutions
The main request is an increase in public funding. Di Maio adds the goal of working with institutions also to change regulations and legislation in favour of independent research.12 Perrone identifies as a priority the simplification of procedures and the removal of bureaucratic obstacles that slow down clinical studies.34 His concrete example is being able to use drugs already reimbursed by the Ssn in routine clinical practice when important scientific questions are being addressed. According to Perrone, the entire “Italian system” would benefit.34
The savings for the National Health Service: what Aiom says
Di Maio argues that some studies could save the Ssn money, for example by testing drugs given in lower quantities or with shorter cycles than those set out in the approval.12 However, he adds, if these treatments cannot be used at the expense of the National Health Service, the studies remain blocked.12
Examples presented at the congress
Perrone cited the Fata study as an example, which in his view shows how institutions and universities can collaborate effectively. The study was funded through the first Aifa call for proposals.4 Also at the congress, Giuseppe Procopio, president of Ficog (Federation of Italian Cooperative Oncology Groups), identified head-to-head studies, which directly compare two therapies, as fundamental. He named Airc and the Umberto Veronesi Foundation as the main non-profit bodies providing support.5 Procopio explained that Ficog has no budget autonomy. Thanks to an agreement with the Veronesi Foundation, however, it can fund one specific disease: 2026 was the year of the pancreas, and from 2027 each year an organ area will be the recipient of a non-sponsored academic research programme.5
What changes
The savings for the Ssn linked to reduced doses or shorter schedules is a hypothesis put forward by Di Maio: its verification depends on the possibility of carrying out precisely those studies.12
This article was written by artificial intelligence from the sources cited, without human review. Automatic newsroom by Redazia.
Sources
Footnotes
-
Tumori, Di Maio (Aiom): ‘servono più risorse pubbliche per la ricerca indipendente’, Adnkronos, 2026-11-15 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10
-
Tumori, Di Maio (Aiom): ‘servono più risorse pubbliche per la ricerca indipendente’, Startupbusiness.it, 2026-11-15 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10
-
Perrone (Fondazione Aiom): “In Italia ricerca clinica indipendente in crisi, servono interventi concreti”, Adnkronos, 2026-11-15 ↩ ↩2 ↩3
-
Perrone (Fondazione Aiom): “In Italia ricerca clinica indipendente in crisi, servono interventi concreti”, Startupbusiness.it, 2026-11-15 ↩ ↩2 ↩3 ↩4
-
Tumori, Procopio (Ficog): ‘fondamentali gli studi testa a testa e il supporto degli enti no profit’, Adnkronos, 2026-11-15 ↩ ↩2


